| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
sales8178@energy-chemical.com |
- Cidofovir dihydrate
-
-
2026-09-16
- CAS:149394-66-1
- Min. Order: 1g
- Purity: 98%-102%
- Supply Ability: 500G
- Cidofovir
-
- $6.00
-
2026-09-02
- CAS:149394-66-1
- Min. Order: 1KG
- Purity: 99%
- Cidofovir USP/EP/BP
-
- $1.10
-
2026-08-20
- CAS:149394-66-1
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Cidofovir dihydrate Basic information |
| | Cidofovir dihydrate Chemical Properties |
| Melting point | >250°C (dec.) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | DMSO (Sparingly), Water (Sparingly) | | form | Solid | | color | White | | InChI | InChI=1/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/s3 | | InChIKey | VWFCHDSQECPREK-ISZMHOAENA-N | | SMILES | N1C(=O)N(C[C@@H](CO)OCP(O)(=O)O)C=CC=1N |&1:5,r| |
| | Cidofovir dihydrate Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | An injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefo
re prevention of viral replication and transcription. It is used in the treatment of acyclovir resistant herpes as well as a complementary intralesional therapy against papillomatosis caused by human
papillomavirus (HPV). | | Uses | Cidofovir Dihydrate is used in treatment of pain and combination with analgesics. | | Definition | ChEBI: The dihydrate of the anhydrous form of cidofovir. A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. | | Brand name | Vistide
(Gilead Sciences). | | in vivo | Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) dihydrate is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice[2].
| Animal Model: | Female weanling BALB/c mice infected with cowpox virus (CPV)[2] | | Dosage: | 100 mg/kg | | Administration: | Subcutaneous injection; 3-6 days interval; 21 days | | Result: | Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection.
Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day. |
|
| | Cidofovir dihydrate Preparation Products And Raw materials |
|